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Abstract 
Triple negative breast cancer (TNBC) is a common subtype of breast cancer comprising about 
15% of the 230,000 new breast cancer cases every year. TNBC is named due to the lack of three 
common receptors that are prevalent in most breast cancer: Estrogen Receptorα (ERα), 
Progesterone Receptor (PR), and Human Epidermal Growth Factor Receptor (HER2). Many 
breast tumors are induced through estrogen and ERα, but these can be treated with endocrine 
therapy which inhibits ERα. The lack of ERα and the other receptors limit drug options to 
chemotherapy regiments which tumors often develop resistance against. Consequently, it is 
important to identify new pathways involved in TNBC and drugs that can provide therapy to 
these patients. One such pathway is the Hedgehog (Hhg) pathway which is upregulated in a 
number of cancers like basal cell carcinoma and medulloblastoma. The Hhg pathway is a highly 
conserved pathway that is important for embryonic development and in controlling cell 
proliferation and differentiation. Due to the Hhg pathway’s selective activation in adult cancer 
cells, it is an ideal candidate for therapeutic intervention. We believe that the Hhg pathway plays 
an important role in TNBC development and can be targeted therapeutically in these patients. 
Here we show that in primary human breast tumors and in TNBC cell lines MDA-MB231, 
MDA-MB468, and BT20 that the Hhg pathway is activated and that it may be regulated in part 
through the PI3K/AKT pathway. We also show that the very promising anti-Hedgehog 
compound GDC-0449, already approved for basal cell carcinomas, can inhibit TNBC cell growth 
in combination with PI3K inhibitor. We intend to test the efficacy of GDC-0449 in combination 
with PI3K inhibitors in vivo to provide a novel targeted therapy for TNBC patients. 
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Problem 
 Triple negative breast cancer is one of the most deadly subtypes of breast cancer that 
accounts for ~15% of the total breast cancer cases and is especially prevalent in the Latino, 
black, and obese populations. The exact mechanism for the initiation and progression of this 
deadly breast cancer subtype has not been established. The purpose of this study is to investigate 
the potential role of the Hedgehog pathway in this process.  This pathway is responsible for cell 
differentiation and body segmentation. It is normally silenced by adulthood but can be 
reactivated in cancers where it contributes to cell proliferation, metastasis, and the maintenance 
of cancer stem cells. We and others have previously shown that the Hedgehog pathway is 
activated in multiple triple negative breast cancer cell lines as well as human breast tumor 
samples. We have suggested a probable mechanism activating the pathway in these cells and a 
possible therapeutic strategy in patients with triple negative breast cancer. 
Background 
Breast cancer and the Triple negative subtype 
Breast cancer is the second most common cancer among women with 230,480 new cases of 
invasive breast cancer and 39,520 deaths in 2011
2
. About 30% of the early diagnosed cases will 
have a recurrence and 50% already have or will develop resistance to chemo or endocrine 
therapy. Triple negative (TN) breast cancer is a common subtype of breast cancer comprising 
about ~15% of the total cases and is especially prevalent among the African, the African-
American, the Latino, and the obese populations
1
.  TN breast cancer comprises several sub-types 
of breast cancer including basal-A and basal-B breast cancer
3
 and more rare forms like 
metaplastic tumors and adenoid-cystic tumors
4
. TN breast cancer is named due to the lack of 
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expression of three common receptors that are frequently associated with most breast cancer: 
Estrogen Receptor α (ERα), Progesterone Receptor (PR), and Human Epidermal Growth Factor 
Receptor 2 (HER2). Estrogen promotes tumor growth by virtue of its non-genomic (growth 
factor signaling through ERα) and genomic effect (transcriptional regulation by ERα). Growth of 
ERα positive breast tumors are stimulated by estrogen and therefore can be treated with anti-
estrogenic therapy like Tamoxifen, which binds to and inhibits ERα function. Other treatment 
options for breast cancer besides endocrine therapy include surgery, radiation, and chemotherapy 
which are often combined in patient treatment. But the lack of ERα and other growth factor 
receptors in TN tumors limit drug treatment options to chemotherapy that often leads to the 
development of resistance. Consequently, it is important to identify new pathways critical for 
growth and survival of TN cancers and develop targeted therapy for these patients. One such 
pathway is the Hedgehog (Hhg) pathway which we show to be upregulated in TN breast cancer 
cell lines (see background data). 
 
 
 
 
 
 
 
 
6 
 
Figure1 
 
The Hedgehog Pathway 
The Hhg pathway is a highly conserved and important embryonic developmental pathway 
that controls cell proliferation and differentiation. By adulthood, the pathway is largely inactive 
other than in stem cell populations and maintaining tissue homeostasis
5
. Activation of the 
pathway has also been heavily implicated in cancer and has been shown to be especially 
prevalent in basal cell carcinoma, medulloblastoma, and pancreatic cancer
6
. More recently, 
activation of Hhg pathway has been demonstrated in many solid tumors such as glioblastoma, 
melanoma, breast, lung, and prostate cancers
7
. The pathway is activated mainly through two 
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different mechanisms: the ligand dependent (canonical) pathway and the ligand independent 
(non-canonical) pathway.  
The ligand dependent pathway involves the inhibition of the membrane bound receptor 
PTCH1 through the Sonic, Desert, or Indian Hedgehog ligand. The inhibition of PTCH, allows 
the release of the G-protein coupled receptor Smoothened (SMO) which in turn activates the GLI 
zinc-finger transcription factors. GLI1 is solely a transcriptional activator, while GLI3 and GLI2 
can act as activators or repressors depending on post-translational modifications
8
 (pathway 
conceptualized in Figure 1
9
). Much of the activity of the pathway in normal vertebrae signaling 
is dependent on a sensory organelle called the primary cilium, discussed in detail later. When 
activated, the GLI proteins upregulate expression of multiple target genes and induce 
proliferation, epithelial mesenchymal transition, angiogenesis, metastasis, and activation of other 
cancer stem cell pathways
10-13
.  
The ligand independent pathway involves the activation of GLI1 and GLI2 downstream of 
PTCH, where binding of hedgehog ligands to PTCH is not important (discussed in detail later). 
In the absence of Hhg pathway activators, the repressor form of GLI3 predominates and inhibits 
transcription of Hhg target genes. Aberrant activation of Hhg signaling has been shown in basal 
cell carcinomas and medulloblastomas with mutations in PTCH1 and SMO
14-15
.  
The Hhg pathway plays an important role in mammary development but is largely inactive in 
adult tissue. Severe ductal morphogenesis and dysplasia results when Ptch1 is disrupted in 
mice
16
. Furthermore it has been shown to play an important role in promoting multiple drug 
resistance via efflux of the drug by an ABC transporter dependent mechanism
17
. 
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Figure 2 
 
 Primary Cilia in the context of Hedgehog and Cancer 
Activation of Hhg pathway depends on trafficking of key signaling molecules (such as 
PTCH, SMO, and GLI) to primary cilium which is a sensory organelle common to epithelial 
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cells in vertebrates. Primary cilia have a continuous yet distinct membrane from the plasma 
membrane and have transition fibers at the base of the cilia to prevent passive diffusion between 
the cilium and rest of the cytosol
16
. This exclusion from the cellular compartment allows the 
primary cilia to be sensitive to the environment without interfering in normal cellular processes. 
Kinesin2 and Dynein are two important proteins involved in protein trafficking along the 
microtubules, which are essential for primary cilium dependent signal transduction pathways like 
Hhg
12,18,19-20
. In ligand dependent Hhg signaling, PTCH, SMO, and the GLI transcription factors 
undergo post-translational modifications predominantly within primary cilia (Figure 2)
18
. In the 
presence of Hh ligand, PTCH is recruited to the primary cilium membrane followed by similar 
translocation of SMO to the primary cilium compartment. Suppressor of Fused (SUFU), a key 
repressor of GLI sequesters GLI proteins within the cell cytoplasm in absence of the Hhg 
ligands. After activation of Hh pathway via ligand binding to PTCH, GLI proteins translocate 
into the primary cilium where the SUFU-GLI complex is disassociated, resulting in GLI 
activation. 
After seeing the importance of the cilia in the context of Hhg signaling, many researchers 
have recently looked into primary cilia expression in human cancer patients. Primary tissue 
samples from renal cell carcinoma
21
, melanoma
22
, basal cell carcinoma
23
, medulloblastoma
24
, 
and pancreatic cancer
25
 patients all showed reduction in primary cilia when compared to adjacent 
normal tissue. In breast cancer, the issue of primary cilium is more complex as a study of 
primary tumors and cell lines of various breast cancer subtypes showed differences in primary 
cilia expression. The basal-B breast cancer subtype, which are TN tumors by definition, were 
shown to be the only breast cancer type to have high amounts of primary cilia in cancer cell lines 
(MDA-MB 231, MDA-MB 435, SUM1315, and Hs578T)
26
 . 
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Non-canonical Signaling of the Hedgehog Pathway 
In recent years it has come to light that the Hhg pathway can be activated in the absence of 
Hhg ligands via cross-talk with other signaling pathways such as the PI3k/AKT and the MEK1/2 
pathways
27-28
. The PI3k/AKT pathway plays a very important role in protecting Gli1 and Gli2 
transcription factors from degradation by inhibiting Protein kinase A. The MEK1/2 pathways 
play an important role in stabilizing Gli1 and Gli2 via MEK1 binding to the N-terminal end of 
the transcription factors. Although the detailed mechanism remains unknown the stabilization 
caused by the MEKs is thought to facilitate nuclear translocation of Gli.  Both PI3k/AKT and 
MEK1/2 pathways are highly active in TN breast cancers
8
 making these pathways very 
intriguing areas of further study.  
Hedgehog and Cancer Therapeutics 
As the Hhg pathway is predominantly activated only in cancer cells in adults, it is an ideal 
candidate for therapeutic intervention. Genentech has recently developed a small molecule anti-
Hedgehog compound named Vismodegib (GDC-0449). By inhibiting SMO, GDC-0449 blocks 
activation of GLI1 and downregulates its target genes. It has already been used in Phase I and 
Phase II clinical trials on patients with advanced basal cell carcinoma showing clinical benefit in 
almost all patients. Last January, GDC-0449 was approved for a Phase III trial by the FDA and 
therefore, could be a therapeutic option for many cancer patients. GDC-0449 has minimal side 
effects when taken orally
29
. Therefore, this small molecule inhibitor could be used to target the 
Hhg pathway in patients with triple negative breast cancers. Several other pharmaceutical 
companies are also developing SMO inhibitors based on the success of GDC-0449 in the clinical 
trials. 
11 
 
Significance 
 Triple negative breast cancer continues to be one of the most deadly subtypes of breast 
cancer especially among the young and minorities. Late detection and lack of targeted therapies 
largely contribute to the poor prognosis of the patients with TN breast cancer. The Hedgehog 
pathway presents a possible alternative therapeutic target that could provide immediate survival 
benefits to patients with TN breast cancer. With the success of anti-Hhg compounds in the clinic 
like Genentech’s GDC-0449 and other anti-Hedgehog compounds ready for clinic trials, 
targeting the Hhg pathway in cancer has become an area of intense therapeutic research. By 
dissecting the complex mechanism of Hhg activation we hope to gain new insights into the 
crosstalk between Hhg and other oncogenic pathways that could in the future be used for 
combination therapy in conjunction with anti-Hhg compounds.  
Hypothesis  
We and others have already shown that the Hhg pathway is activated in TN breast cancer cell 
lines and primary human tumors
11
 (see background data). Based on our own data as well as 
others we hypothesize that altered expression of Gli1 in TN breast cancer cell lines, due to a 
complex crosstalk with other oncogenic pathways, is contributing to increased Hedgehog 
signaling and therefore tumorigenesis.  Furthermore, silencing this pathway could provide 
therapeutic benefits to patients.  
 Objectives: 
Specific aim 1: Decipher the mechanism underlying the upregulation of the Hedgehog 
pathway in triple negative breast cancer by exploring potential cross-talk with other 
signaling pathways. 
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 Our group (manuscript submitted) and others have shown a cross-talk between the 
PI3k/AKT and Hhg pathway that results in activation of Hhg
11
. Because of high PI3k/AKT 
activity in TN breast cancer, there is a strong rationale to delve deeper into the possible cross-
talk between the two pathways and determine if any other signaling mechanism contributes to 
Hhg activation in TN breast cancer.  
Specific aim 2: Identify key downstream targets of Gli1 contributing to tumorigenesis.  
 In other cancers, several downstream targets of the Hedgehog pathway, involved in 
metastasis, proliferation, stem cell characteristics, and angiogenesis have been identified. We 
will look at known targets of the Hhg pathway as well as other genes within the Hhg pathway to 
further characterize the pathway within TN breast cancer. 
Specific aim 3: Assess the efficacy of anti-Hhg compounds in terms of cancer therapeutics. 
 In recent years, the Hhg pathway has been shown to be an ideal target for developing 
small molecule inhibitors and many pharmaceutical companies have manufactured targeted 
therapies against SMO and GLI1. We will test the efficacy of some of these compounds as well 
as the endogenous repressors of the pathway in TN breast cancer. 
Study Design  
Specific aim 1: Decipher the mechanism behind the upregulation of the Hedgehog pathway 
in triple negative breast cancer by exploring the potential cross-talk with other signaling 
pathways. 
We have previously shown the importance of the PI3K/AKT pathway in regulating GLI 
transcription factor (Figure 3), making it a strong candidate for further investigation. It is 
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therefore, important to study if a cross-talk between the two pathways could regulate the 
aggressive nature of TN breast cancer. Using common TN cell lines, MDA-MB231 and MDA-
MB-468, we will further explore the relationship between these pathways as outlined below. 
Figure 3 
 
Confirming the role of the PI3K/AKT pathway in TNBC Hedgehog Signaling 
To confirm the role of PI3k/AKT in activating Hhg signaling, we will use a constitutively 
active (overexpression) and dominant-negative mutants of PI3k and AKT
19
. These plasmids will 
be transfected into TN breast cancer cell lines and the transactivation potential of GLI will be 
analyzed using the 8x GLI-luciferase plasmid (described in materials and methods). We will also 
14 
 
use the PI3k/AKT inhibitor LY2940002 to test whether its inhibitory effect could be rescued by 
overexpression of constitutively active PI3k/AKT. This will demonstrate the specificity of 
PI3k/AKT in regulating Hedgehog pathway. Upon completion of these experiments we will 
further analyze the downstream signaling events that regulated Gli1 activation through the PI3k 
pathway. 
Specific aim 2: Identify key downstream targets of Gli1 contributing to tumorigenesis.  
 Using Real-time PCR, we aim to identify genes differentially expressed between TN cell 
lines and controls. We will test several known targets of the Hhg pathway involved in 
tumorigenesis as well as other genes involved within Hhg in order to characterize the pathway in 
TN breast cancer cells further. 
Specific aim 3: Assess the efficacy of anti-Hhg compounds as well as the endogenous 
suppressor of Hedgehog pathway in terms of cancer therapeutics. 
 We first will determine the effect of anti-Hhg compounds on TN breast cancer cell lines 
in vitro. Based on these studies, we hope to use these compounds to attenuate the growth of 
tumors induced in mice with TN breast cancer cells. This could lead to clinical trials in patients 
with TN breast cancer in the future. We will focus our attention on the small molecule inhibitor 
of SMO,   GDC-0449; the small molecule inhibitor of GLI1, GANT61
30
. 
Methods 
Tissue culture 
Established triple negative breast cancer cell lines, MDA-MB 231, MDA-MB 436, and 
MDA-MB 468 were cultured in DMEM with 10% fetal bovine serum (FBS) (Sigma Aldrich). 
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Triple negative BT-20 cells were cultured in MEM and 10% FBS, while ERα positive cell lines 
T47D and BT474 were cultured in RPMI 1640 with 10% FBS. The ERα positive cell line MCF7 
was cultured in DMEM with 5% FBS and 6ng/mL insulin. The MCF10A, normal breast 
epithelium cell line established from a triple negative breast cancer patient, was cultured in 
DMEM/F12 media supplemented with 10% FBS, cholera toxin, insulin, hydrocortisone, and 
EGF. All media and supplements were obtained from Sigma Aldrich and cells were cultured at 
37˚C in a 5% CO2 saturated incubator. 
RNA and Protein 
Cells were grown to 70-80% confluency, washed with 1x PBS and then harvested for 
RNA isolation using Trizol (Sigma) or for protein extraction. RNA was isolated and cDNA made 
using High Capacity cDNA kit (AB Biosciences). Real-time PCR was performed with the cDNA 
to assess mRNA levels in the cells by using Taqman assays (AB Biosciences) and SYBR-Green 
chemistry (Sigma) (primer sequences available upon request.) Semi quantitative PCR 
amplification was performed with the cDNA and the products were visualized on agarose gels. 
Protein was extracted using cell lysis buffer, sonicated and used for western blots. Protein 
was separated on SDS-PAGE gels and then transferred to a nitro-cellulose membrane and probed 
for proteins of interest using specific antibodies. Anti-α/β Tubulin rabbit polyclonal antibody 
(#2148) was obtained from Cell Signaling Technology, Gli1 mouse monoclonal antibody (SC-
271075) was bought from Santa Cruz Biotechnology, Smoothened (Smo) rabbit polyclonal 
antibody was from Abcam (Ab38686). 
Transfections and Luciferase Assays 
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Cells were transfected using Lipofectamine 2000 (Sigma Aldrich) in antibiotic free media 
at 75% confluency and the media was changed 16 hours post-transfection. 8x-Gli-δ51-LucII and 
8xm-Gli-δ51-LucII were generous gifts from Dr. Hidenao Sasaki of Hokkaido University, 
Japan
31
. The plasmid allows for the quantification of the activity of the Gli1 transcription factor. 
Eight repeats of the Gli1 binding sequence is cloned in front of the minimal promoter of the δ-
crystalline gene that drives the expression of luciferase from the plasmid. This allows the Gli1 
transcription factor to bind to the sequence and activate the transcription of luciferase which can 
be quantified using the Dual Luciferase Assay kit (Promega) (see figure 4). To ensure that the 
luciferase expression is due to Gli-mediated activation, we used an identical plasmid where Gli1 
binding site was mutated. The pRL-TK vector where renilla luciferase expression is driven by 
thymidylate kinase promoter was also transfected into the cells, which served as the internal 
control. Cells were harvested at times varying from 36-48 hours after transfection (see 
experiments for specific time). GDC-0449 was purchases from Dr. Ching Shih-Chen’s lab at The 
Ohio State University while U0126 and LY2940002 were purchased from Sigma Aldrich. Drugs 
and/or ligands were added to the transfected cells 16 hours post-transfection. Recombined Sonic 
Hedgehog Ligand was obtained from R&D Systems. 
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Figure 4 
 
MTT Assays 
In vitro cell proliferation assays were carried out according to the MTT assay protocol provided 
with the kit (Roche). MB-231, MB-436, and MB-468 cells were seeded in 96 well plates, 
starved, and then treated with drugs for varying lengths of time. Cell growth is quantified by 
using a spectrophotometer to measure absorbance in the wells. All assays were done in 
quadruplicate.   
Background Data 
The Hedgehog Pathway is activated in Triple Negative Breast Cancer Cell Lines and 
Correlates with Poor Disease Free Survival in ERα Negative Patients 
18 
 
TN breast cancer cell lines BT-20, MB-231, and MB-468 and ERα positive cell lines 
T47D and ZR 75.1 were harvested and protein extracted for Western blot analysis. All three TN 
breast cancer cell lines showed significantly higher level of SMO expression, compared to the 
ERα positive cell lines (Figure 5a). Protein was normalized to α/β Tubulin and quantified using 
ImageJ software (Figure 5b.). We also found GLI1 to be highly expressed in the TN cell lines 
when compared to the ERα positive cell line OHTR (Tamoxifen resistant MCF7 cells) and 
normal breast epithelium MCF10A cells (Figure 6a). Protein was again normalized to α/β 
Tubulin (Figure 6b). Total RNA was isolated from all the TN cell lines and MCF7 cells (an ERα 
positive cell line), and GLI1 expression was analyzed using Taqman Real-Time PCR and 
normalized to β-actin. The data showed significant upregulation of GLI1 in the TN cell lines 
compared to MCF7 cells (Figure 6c).  
In collaboration with Dr. Bhuvaneswari Ramaswamy, we were also able to show that 
high Gli1 expression in breast cancer patients with estrogen receptor negative disease correlates 
significantly with poor disease free survival (Figure 7) [n=230]. Tissue microarray prepared from 
Patients with TN breast cancer were assayed using immunohistochemistry for Gli1 expression, 
scored by pathologists, and scored for high and low Gli1 expression..  About 60% of the patients 
in the cohort were in the high Gli1 expressing subgroup. This data strongly highlights the 
importance and relationship between Hedgehog signaling and poor patient outcome and shows 
that Hedgehog status could be an important prognostic marker for patients with TN breast 
cancer. 
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Figure 5 
 
Figure 6 
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Figure 7 
 
 
Results 
The PI3k/AKT pathways play important roles in Hedgehog signaling in TN Cell lines 
 The PI3k/AKT and MEK1/2 pathways are both known to play important roles in the 
activation of Hedgehog signaling in NIH3T3 cells. We assessed the effect of these pathways on 
Gli1 transcriptional activation by using an 8x Gli-luciferase plasmid assay. The plasmid 
constructs are shown in Figure 4 and described in the materials and method section. Cells were 
transfected with either the wild type or the mutant 8x Gli construct, media was changed 12 hours 
after transfection and then cells were treated with their respective drug. To assess individual 
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pathways effect, we used small molecule inhibitors specific for the respective pathways. 
LY2940002 is an established PI3K/AKT pathway inhibitor; U0126 is an inhibitor of the 
MEK1/2 pathways, while GDC-0449 is a drug in clinical trials for inhibiting the Hedgehog 
pathway by blocking SMO. After 36 hours of drug treatment the cells were harvested and 
luciferase expression analyzed.  LY294002 inhibited Gli1 activation by ~ 50% while U0126 and 
GDC-0449 inhibited it by 30% (Figure 3). Luciferase expression from the mutant plasmid was 
not affected significantly, indicating the specificity of the assay and the drugs (data not shown).  
To further characterize PI3k’s affect on the Hhg pathway we transfected MB-231 cells 
with a series of PI3k and AKT expression vectors. We used a PI3k control vector (PBJ1), PI3k 
overexpression vector (P110* O/E), PI3k dominant negative vector (P110* K/R), AKT control 
vector (AKT-Con), AKT overexpression (AKT-myr O/E), and AKT dominant negative vector 
(AKT-K/R)
32
. To first test the extent of PI3k and AKT overexpression we isolated RNA after 
transfecting MB-231 cells and PCR amplified PI3k, AKT, and β-actin (loading control) 
transcripts. The PCR products were then separated on an agarose gel and quantified using 
ImageJ software (Figure 8a and 8b). The transfection efficiency of vectors expressing 
constitutively active and dominant negative AKT were very high but the PI3k was overexpressed 
at a moderate level. When cotransfected with the 8x Gli luciferase reporter plasmid in MB231 
cells, the PI3k overexpression vector again showed moderate increase in Gli transcriptional 
activity. We are currently assaying the effects of AKT vectors on Gli transcriptional activity.  
This data suggests importance of PI3K/AKT pathway in regulating Hhg signaling in TN breast 
cancer and will continue to be investigated further. 
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Figure 8 
 
Other Hedgehog Molecules and Gli1 Target Genes are upregulated in TN Cell lines 
Total RNA from TN cell lines and MCF10A cells was isolated, subjected to Real-Time 
RT-PCR, and normalized to RPLPO. Sonic Hedgehog ligand (Shh) was seen to be high only in 
one TN cell lines, MB-231 (Figure 9a). This indicates the possibility that the Hhg pathway 
activation in some TN cells may not be occurring via canonical pathway activation. GLI2, which 
can function both as a transcriptional repressor and an activator, was upregulated in MB 231 and 
BT-20 TN cells but not MB-468 cells. Further work needs to be done to determine the role of 
GLI2 in these cells. Activation of other Hedgehog components except SMO and GLI1 seem to 
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be cell type specific. GLI1 transcriptional targets however were upregulated in TN cell lines 
when assayed by Real-time PCR. SNAIL1 and FOXM1 are both known targets
33
 of Hhg 
pathway and were highly expressed in TN breast cancer cell lines when compared to normal 
breast epithelial MCF10A cells.  
Figure 9 
 
Effect of Anti-Hedgehog compounds alone and in combination with other targeted 
therapies on TN breast cancer cell lines: 
24 
 
 With recent advances in the development of anti-Hhg compounds we wanted to test the 
therapeutic potential of targeting the Hhg pathway in TN cell lines. We tested two anti-Hhg 
compounds, Genentech’s GDC-0449, a small molecule inhibitor of Smo currently in Phase III 
clinical trials for basal cell carcinoma, and the small molecule inhibitor GANT61 which inhibits 
the GLI transcription factors. We used MB 231 cells initially to test the efficacy of GDC-0449 
alone in inhibiting cell proliferation rates but found the cells to be highly resistant to the drug 
[data not shown].  
 Based on our previous data we hypothesized the involvement of the PI3k pathway in 
activating Hhg signaling in TN breast cancer. We therefore tested the effect of combining PI3k 
and Hhg targeted therapies on these cells. LY294002 is a well established PI3k inhibitor 
commonly used in vitro and in vivo studies. We tested the effects of GDC0449 alone and in 
combination with LY294002 on MB231 cells in a MTT assay and using the 8x Gli luciferase 
reporter system. The MTT time course experiment showed relatively little growth inhibitory 
effects by GDC0449 (25uM) alone, but the LY294002 (20uM) alone showed significant growth 
inhibition (Figure 10a). When combined the two treatments resulting in further growth inhibition 
but not substantially different from the LY294002 alone treatment. The luciferase assay showed 
a similar pattern as inhibition of the GLI transcriptional activity was largely due to LY294002 
and GDC0449 had a small contribution to inhibiting transcription (Figure 10b). Next we 
determined the effect of this combination therapy on MB-468 and MB-436 cell lines in vitro. We 
had seen in previous experiments that MB-468 cells were more sensitive to GDC0449 alone and 
decided to test two concentrations of the drug alone and in combination with LY294002 (Figure 
10b). Again we saw significant inhibition of cell growth by LY294002 and a relatively minor 
effect of GDC-0449. This overall resistance to the anti-Smo compound, GDC0449, led us to 
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investigate if we could inhibit cell growth by targeting the Hhg pathway further downstream of 
Smo. 
 For this purpose we tested the effect of GANT61, a potent GLI targeting small molecule, 
on the TN cell lines. We first treated MB-231 and MB-468 cells with varying concentrations of 
GANT61 (10 uM, 25 uM, and 50 uM) and found major inhibition of cell proliferation over a 72 
hour period [Figure 11a and 11b]. Next we compared the effect of GANT61 alone and in 
combination with LY294002 to test the therapeutic potential of combined targeting of GLI and 
PI3K pathway (Figure 11c). GANT61 treatment alone resulted in ~40% inhibition of MB231 cell 
proliferation while there was ~25% inhibition in presence of LY294002. When combined 
together, GANT61 and LY294002 had an additive effect on cell proliferation resulting in ~60% 
inhibition. This data suggests that GANT61 could be a more potent inhibitor of the TN breast 
cancer cells compared to GDC0449.  
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Figure 10 
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Figure 11 
 
Discussion 
Our data indicates that the Hedgehog pathway is activated in triple negative breast cancer 
cells and that this activation results from cross-talk with other signaling pathways activated 
during carcinogenesis. The key signaling molecules in Hedgehog pathway, SMO and GLI1, are 
upregulated in triple negative cell lines. Other groups have shown the importance of the pathway 
by knocking down Gli1 in MB231 cells and seeing a significant growth inhibition compared to 
the control cells
13
.   
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We investigated the mechanism behind upregulation of the Hhg pathway and our data 
suggests the importance of other cell signaling pathways in regulating the Hedgehog pathway. 
Using an 8x Gli-Luciferase reporter assay we have showed the importance of the MEK1/2 
pathways but also the PI3K/AKT pathways, suggesting the involvement of other signaling 
pathways in Hedgehog activation. We also used PI3k overexpression vector in conjunction with 
the luciferase reporter system to show that constitutively active PI3k activates GLI 
transcriptional activity. Further investigation of the mechanism involved is currently underway. 
Lastly, we tested the possible therapeutic implications of targeting the Hhg pathway in 
TN breast cancer. We used two anti-Hhg compounds that target different proteins in the Hhg 
pathway, which yielded very different results. Most TN cells, especially MB231, were markedly 
resistant to GDC-0449, the Smo inhibitor that is being tested in Phase III clinical trials in basal 
cell carcinoma. We next looked at a combination therapy based approach utilizing our 
observation that the PI3k pathway is important for GLI activation. We used the common PI3k 
inhibitor LY294002 alone and in combination with GDC0449 and found most of the inhibitory 
effects on GLI activation and cell proliferation were due predominantly to LY294002. The 
mechanism contributing the resistance to GDC0449 remains unclear and is an area of future 
investigation for us. 
Noting the resistance to the upstream protein Smo, we decided to test an inhibitor of Hhg 
that targets the pathway further downstream. GANT61 specifically targets the Gli1 transcription 
factors, blocking major transcriptional activity of the Hhg pathway. We tested this compound 
alone and in combination with LY294002 on cell growth. GANT61 showed a much higher 
potency against MB-231 and MB-468 cells compared to GDC-0449. When compared to the PI3k 
inhibitor, LY294002, we found the GANT61 to have higher efficacy in inhibiting MB-231 cells 
29 
 
compared to LY294002, and the combination had an additive effect. Although GANT61 is not in 
clinical trials, a strategy to inhibit GLI1 could be a potential option to inhibit Hhg pathway. Our 
studies clearly shows that therapeutic targeting of the Hhg pathway, especially in combination 
with  PI3k pathway could be a rationale approach in treating patients with TN breast cancer. 
With GDC-0449 already approved for clinical use, it is important for us to find the mechanism 
underlying reduced response of the TN cells to SMO inhibitors.  
There is a critical need to both understand and to develop new therapies for triple 
negative breast cancer. Our studies here show that the Hedgehog pathway is activated in triple 
negative breast cancer and that this activation may be in part due to other signaling pathways 
(summarized with inhibitors in figure 12). We show here the therapeutic potential in vitro, as 
well as some of the difficulty in targeting the pathway. Future studies will determine the 
importance of the downstream target genes of the active GLI transcription factors, validate the 
mechanism behind its upregulation, and test the efficacy of anti-Hedgehog therapeutics in vivo. 
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